Actuate Therapeutics Reports Positive Phase II Results for Elraglusib in Advanced Salivary Gland Cancers
Key Insights
Actuate Therapeutics (search) reported positive Phase II results for elraglusib combined with platinum-based chemotherapy in advanced metastatic salivary gland cancers (search).
The study achieved a median overall survival of 18.6 months across all patients, with non-ACC patients showing particularly strong results at 27.8 months.
Median progression-free survival reached 6.4 months, with 27% of patients remaining progression-free at one year.
Actuate Therapeutics (search), Inc. (ACTU) announced positive results from a Phase II clinical trial evaluating elraglusib in combination with carboplatin or cisplatin for patients with advanced metastatic salivary gland cancers (search). The study included both adenoid cystic carcinoma (search) (ACC) and other salivary gland cancer subtypes, with results published in Clinical Cancer Research.
Study Design and Patient Population
The Phase II trial enrolled patients with advanced metastatic salivary gland cancers (search), with 47% having adenoid cystic carcinoma (search) and 53% having non-ACC subtypes. Patients received elraglusib in combination with either carboplatin or cisplatin as part of the treatment regimen.
Overall Survival Outcomes
The study demonstrated a median overall survival of 18.6 months across all enrolled patients. Survival rates showed 58% of patients alive at one year and 40% alive at two years. Non-ACC patients showed particularly encouraging results, achieving a median overall survival of 27.8 months, substantially longer than the overall population median.
Progression-Free Survival Results
Median progression-free survival reached 6.4 months for the overall study population. Notably, 27% of patients remained progression-free at the one-year mark. When compared to historical progression-free survival estimates, the results showed mixed outcomes relative to established benchmarks: historical PFS estimates suggest 49 months for ACC patients and less than 6 months for non-ACC patients.
Market Response
Following the announcement of these positive Phase II results, Actuate Therapeutics (search) shares rose more than 4% in pre-market trading. This followed the stock's Friday closing price of $7.52, which represented a 1.35% increase from the previous trading session.